Iovance Biotherapeutics (IOVA) Cash from Operations (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Cash from Operations of 72100000.0 for Q1 2026, up 30.47% year-over-year from 55262383.95 in Q1 2025, and down 37.18% quarter-over-quarter from 52557000.0 in Q4 2025.
Iovance Biotherapeutics (IOVA) Cash from Operations (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Cash from Operations for 15 consecutive years, with 72100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 30.47% year-over-year to 72100000.0; the TTM figure through Mar 2026 stood at 270806000.0 (up 19.02% YoY), while the FY2025 annual figure was 302400000.0, up 14.33% from the prior year.
- Cash from Operations slipped to 72100000.0 in Q1 2026 per IOVA's latest filing, from 52557000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 52557000.0 in Q4 2025 and bottomed at 122279000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 81297294.12 across 5 years, with a median of 77671000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 44.24% — and 2025, when it jumped 31.52%.
- Iovance Biotherapeutics' Cash from Operations stood at 77671000.0 in 2022, then fell by 8.11% to 83970000.0 in 2023, then climbed by 12.71% to 73296000.0 in 2024, then increased by 28.29% to 52557000.0 in 2025, then sank by 37.18% to 72100000.0 in 2026.
- Business Quant data shows IOVA's Cash from Operations at 72100000.0 in Q1 2026, 52557000.0 in Q4 2025, and 78743000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -60.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.82 Mn |
| Jun 30, 2026 | -60.82 Mn |
| Mar 31, 2026 | -72.10 Mn |
| Mar 31, 2026 | -72.10 Mn |
| Dec 31, 2025 | -52.56 Mn |
| Dec 31, 2025 | -52.56 Mn |
| Sep 30, 2025 | -78.74 Mn |
| Sep 30, 2025 | -78.74 Mn |
| Jun 30, 2025 | -67.41 Mn |
| Jun 30, 2025 | -67.41 Mn |
| Mar 31, 2025 | -103.69 Mn |
| Mar 31, 2025 | -103.69 Mn |
| Dec 31, 2024 | -73.30 Mn |
| Dec 31, 2024 | -73.30 Mn |
| Sep 30, 2024 | -58.97 Mn |
| Sep 30, 2024 | -58.97 Mn |
| Jun 30, 2024 | -98.43 Mn |
| Jun 30, 2024 | -98.43 Mn |
| Mar 31, 2024 | -122.28 Mn |
| Mar 31, 2024 | -122.28 Mn |